Peter Herrlich
Peter Herrlich has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Helmut Ponta
Forschungszentrum Karlsruhe, Institut für Toxikologie und Genetik, Postfach 3640, D‐76021 Karlsruhe, Germany
3 shared publicationsAlex J. van der Eb
Laboratory for Molecular Carcinogenesis, Sylvius Laboratories, University of Leiden, 2300 RA Leiden, The Netherlands; 2Forschungszentrum Karlsruhe, Institute of Genetics, 76021 Karlsruhe, Germany; 3Unité de Virologie Humaine, Institut National de la Santé et de la Recherche Médicale (INSERM)-U412, Ecole Normale Supérieure, Lyon Cedex 07, France; 4Department of Signal Transduction and Growth Control, Deutsches Krebsforschungszentrum, Heidelberg, Germany
1 shared publicationDavid Wainwright
1 shared publicationEmmanuel Vial
Laboratory for Molecular Carcinogenesis, Sylvius Laboratories, University of Leiden, 2300 RA Leiden, The Netherlands; 2Forschungszentrum Karlsruhe, Institute of Genetics, 76021 Karlsruhe, Germany; 3Unité de Virologie Humaine, Institut National de la Santé et de la Recherche Médicale (INSERM)-U412, Ecole Normale Supérieure, Lyon Cedex 07, France; 4Department of Signal Transduction and Growth Control, Deutsches Krebsforschungszentrum, Heidelberg, Germany
1 shared publicationFrank D Böhmer
Molecular Cell Biology Research Unit, Klinikum, Friedrich-Schiller-University, Drackendorfer Str. 1, D-07747 Jena, Germany
1 shared publication- Hans van Dam
Department of Cell and Chemical Biology Leiden University Medical Center (LUMC) Einthovenweg 20 2333ZC Leiden The Netherlands
1 shared publication
Latest Publications
- 1 June 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 910 (1) , 106-120
CD44 Acts Both as a Growth‐ and Invasiveness‐Promoting Molecule and as a Tumor‐Suppressing Cofactor
Abstract: High‐molecular‐weight splice variants of the CD44 transmembrane protein family have been implicated in tumorigenesis and metastasis formation. By contrast, in certain tumors‐for example, Burkitt's lymphoma, neuroblastomas, and prostate cancer‐loss of CD44 expression seems to accompany transformation. Here we describe two modes of action of CD44 proteins. They can bind growth factors and present them to their authentic high‐affinity receptors, and thus promote proliferation and invasiveness of cells. Under these conditions the CD44 proteins recruit ERM proteins‐for example, ezrin or moesin‐to their cytoplasmic tails, thereby producing links to the cytoskeleton. This mode of action could account for the tumor‐promoting action of CD44 proteins. The second mode of action of CD44 proteins comes into play when cells reach confluent growth conditions. Under specific conditions, binding of another ligand, the ECM component hyaluronate, leads to the activation and binding to the CD44 cytoplasmic tail of the tumor suppressor protein merlin. The activation of merlin confers growth arrest, so‐called contact inhibition. This function of CD44 proteins defines them as tumor suppressors. The type of action of CD44 on a given cell will depend on the isoform pattern of CD44 expressed, on the cellular equipment with ERM protein members, on the nature of the ECM, and on yet‐unknown conditions.
- 1 June 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 910 (1) , 106-120
CD44 Acts Both as a Growth‐ and Invasiveness‐Promoting Molecule and as a Tumor‐Suppressing Cofactor
Abstract: High‐molecular‐weight splice variants of the CD44 transmembrane protein family have been implicated in tumorigenesis and metastasis formation. By contrast, in certain tumors‐for example, Burkitt's lymphoma, neuroblastomas, and prostate cancer‐loss of CD44 expression seems to accompany transformation. Here we describe two modes of action of CD44 proteins. They can bind growth factors and present them to their authentic high‐affinity receptors, and thus promote proliferation and invasiveness of cells. Under these conditions the CD44 proteins recruit ERM proteins‐for example, ezrin or moesin‐to their cytoplasmic tails, thereby producing links to the cytoskeleton. This mode of action could account for the tumor‐promoting action of CD44 proteins. The second mode of action of CD44 proteins comes into play when cells reach confluent growth conditions. Under specific conditions, binding of another ligand, the ECM component hyaluronate, leads to the activation and binding to the CD44 cytoplasmic tail of the tumor suppressor protein merlin. The activation of merlin confers growth arrest, so‐called contact inhibition. This function of CD44 proteins defines them as tumor suppressors. The type of action of CD44 on a given cell will depend on the isoform pattern of CD44 expressed, on the cellular equipment with ERM protein members, on the nature of the ECM, and on yet‐unknown conditions.
- 1 January 2000
- Published by Elsevier in Biochemical Pharmacology
- Vol. 59 (1) , 35-41
Redox regulation of signal transduction in mammalian cells
- 1 January 2000
- Published by Elsevier in Biochemical Pharmacology
- Vol. 59 (1) , 35-41
Redox regulation of signal transduction in mammalian cells
- Open Access
- 1 August 1999
- Published by American Society of Hematology in Blood
- Vol. 94 (3) , 940-949
Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From Bone Marrow Macrophages
The glycosaminoglycan hyaluronate (HA) is part of the extracellular environment in bone marrow. We show here that HA activates signal transduction cascades important for hemopoiesis. In myeloid and lymphoid long-term bone marrow cultures (LTBMC), treatment with hyaluronidase (HA’ase) results in reduced production of both progenitor and mature cells. Exogeneous HA added to LTBMC had the opposite effect: it enhanced hematopoiesis. The effect of HA is mediated through two different HA receptors on bone marrow macrophage-like cells, one of which is CD44 while the other is unknown. HA induces bone marrow macrophages to secrete IL-1β (CD44-dependent) and IL-6 (CD44-independent). The two receptors address different signal transduction pathways: CD44 links to a pathway activating p38 protein kinase while the other yet unknown receptor induces Erk activity. There was no difference of the effect of HA and HA’ase on hematopoiesis in LTBMC and on cytokine production by macrophages in CD44-deficient mice compared with wild-type mice, indicating that the CD44 hyaluronate receptor and its signal transduction can be compensated for. Our data suggest a regulatory role for the extracellular matrix component HA in hematopoiesis and show the induction of signal transduction by HA receptors.
- 1 August 1999
- Published by American Society of Hematology in Blood
- Vol. 94 (3) , 940-949
Open AccessHyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From Bone Marrow Macrophages
The glycosaminoglycan hyaluronate (HA) is part of the extracellular environment in bone marrow. We show here that HA activates signal transduction cascades important for hemopoiesis. In myeloid and lymphoid long-term bone marrow cultures (LTBMC), treatment with hyaluronidase (HA’ase) results in reduced production of both progenitor and mature cells. Exogeneous HA added to LTBMC had the opposite effect: it enhanced hematopoiesis. The effect of HA is mediated through two different HA receptors on bone marrow macrophage-like cells, one of which is CD44 while the other is unknown. HA induces bone marrow macrophages to secrete IL-1β (CD44-dependent) and IL-6 (CD44-independent). The two receptors address different signal transduction pathways: CD44 links to a pathway activating p38 protein kinase while the other yet unknown receptor induces Erk activity. There was no difference of the effect of HA and HA’ase on hematopoiesis in LTBMC and on cytokine production by macrophages in CD44-deficient mice compared with wild-type mice, indicating that the CD44 hyaluronate receptor and its signal transduction can be compensated for. Our data suggest a regulatory role for the extracellular matrix component HA in hematopoiesis and show the induction of signal transduction by HA receptors.
- Open Access
- 15 April 1998
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 12 (8) , 1227-1239
Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation
Cellular transformation can be achieved by constitutive activation of growth-regulatory signaling pathways, which, in turn, activate nuclear transcription factors thought to execute a transformation-specific program of gene expression. Members of the dimeric transcription factor family AP-1 are at the receiving end of such growth-regulating pathways and the viral form of the AP-1 subunit Jun establishes one important aspect of transformation in chick embryo fibroblasts (CEFs): enhanced growth in agar and in low serum. Enhanced Jun activity is likely to target several different genetic programs as Jun forms heterodimers with one of several members of the Fos and ATF2 subfamilies, resulting in transcription factors with different sequence specificities. To identify the programs relevant for transformation, we have reduced the complexity of AP-1 factors by constructing Jun bZip mutants that can efficiently dimerize and transactivate with only a restricted set of partner subunits. Upon introduction into CEFs, a Jun mutant selective for the Fos family induced anchorage-independent growth but no growth factor-independence. In contrast, a c-Jun mutant with preference for ATF2-like proteins caused growth factor-independence, but no growth in agar. Coexpression of both mutants reestablished the combined transformation program as induced by wild-type Jun. These data show that Jun-dependent cell transformation can be resolved into at least two distinct and independent processes, anchorage and growth factor independence, obviously triggered by two classes of Jun heterodimers likely regulating different sets of target genes.
- 15 April 1998
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 12 (8) , 1227-1239
Open AccessAutocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation
Cellular transformation can be achieved by constitutive activation of growth-regulatory signaling pathways, which, in turn, activate nuclear transcription factors thought to execute a transformation-specific program of gene expression. Members of the dimeric transcription factor family AP-1 are at the receiving end of such growth-regulating pathways and the viral form of the AP-1 subunit Jun establishes one important aspect of transformation in chick embryo fibroblasts (CEFs): enhanced growth in agar and in low serum. Enhanced Jun activity is likely to target several different genetic programs as Jun forms heterodimers with one of several members of the Fos and ATF2 subfamilies, resulting in transcription factors with different sequence specificities. To identify the programs relevant for transformation, we have reduced the complexity of AP-1 factors by constructing Jun bZip mutants that can efficiently dimerize and transactivate with only a restricted set of partner subunits. Upon introduction into CEFs, a Jun mutant selective for the Fos family induced anchorage-independent growth but no growth factor-independence. In contrast, a c-Jun mutant with preference for ATF2-like proteins caused growth factor-independence, but no growth in agar. Coexpression of both mutants reestablished the combined transformation program as induced by wild-type Jun. These data show that Jun-dependent cell transformation can be resolved into at least two distinct and independent processes, anchorage and growth factor independence, obviously triggered by two classes of Jun heterodimers likely regulating different sets of target genes.
- Open Access
- 1 April 1998
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 12 (7) , 1058-1071
A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth
Signals from the apical ectodermal ridge (AER) of the developing vertebrate limb, including fibroblast growth factor-8 (FGF-8), can maintain limb mesenchymal cells in a proliferative state. We report here that a specific CD44 splice variant is crucial for the proliferation of these mesenchymal cells. Epitopes carried by this variant colocalize temporally and spatially with FGF-8 in the AER throughout early limb development. A splice variant containing the same sequences expressed on model cells binds both FGF-4 and FGF-8 and stimulates mesenchymal cells in vitro. When applied to the AER, an antibody against a specific CD44 epitope blocks FGF presentation and inhibits limb outgrowth. Therefore, CD44 is necessary for limb development and functions in a novel growth factor presentation mechanism likely relevant in other physiological and pathological situations where a cell surface protein presents a signaling molecule to a neighboring cell.
- 1 April 1998
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 12 (7) , 1058-1071
Open AccessA splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth
Signals from the apical ectodermal ridge (AER) of the developing vertebrate limb, including fibroblast growth factor-8 (FGF-8), can maintain limb mesenchymal cells in a proliferative state. We report here that a specific CD44 splice variant is crucial for the proliferation of these mesenchymal cells. Epitopes carried by this variant colocalize temporally and spatially with FGF-8 in the AER throughout early limb development. A splice variant containing the same sequences expressed on model cells binds both FGF-4 and FGF-8 and stimulates mesenchymal cells in vitro. When applied to the AER, an antibody against a specific CD44 epitope blocks FGF presentation and inhibits limb outgrowth. Therefore, CD44 is necessary for limb development and functions in a novel growth factor presentation mechanism likely relevant in other physiological and pathological situations where a cell surface protein presents a signaling molecule to a neighboring cell.
- 1 January 1998
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 3 (4) , d650-656
The CD44 protein family roles in embryogenesis and tumor progression
Members of the CD44 protein family are engaged in various physiological and pathological processes such as lymphocyte activation, lymphocyte homing, wound healing, delayed type hypersensitivity, apoptosis, tumor progression and limb development. Here we summarize observations which lead to a molecular understanding of the function of CD44 in some of these physiological processes. The most striking function for a CD44 variant protein is its presentation of growth factors to high affinity receptors on mesenchymal cells in the developing limb. Furthermore we summarize the experiments that allowed the identification of CD44 variant exon encoded sequences which account for differentiation-specific and inducible splice regulation.
- 1 January 1998
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 3 (4) , d650-656
The CD44 protein family roles in embryogenesis and tumor progression
Members of the CD44 protein family are engaged in various physiological and pathological processes such as lymphocyte activation, lymphocyte homing, wound healing, delayed type hypersensitivity, apoptosis, tumor progression and limb development. Here we summarize observations which lead to a molecular understanding of the function of CD44 in some of these physiological processes. The most striking function for a CD44 variant protein is its presentation of growth factors to high affinity receptors on mesenchymal cells in the developing limb. Furthermore we summarize the experiments that allowed the identification of CD44 variant exon encoded sequences which account for differentiation-specific and inducible splice regulation.